Close

04.21.2017

UW Medicine spurs tech economic growth

The  Milken Institute has ranked the  University of Washington  7th in technology transfer, largely due to its success in licensing medical, biological, engineering, computing and other innovations

The UW received  the highest score in licenses issued.  It was the only institution to file more than 1,000 licenses between 2012-2015. 

Its licensing income of $42.8 million in 2015 was another strength pushing up its placement in the rankings.  It was ranked 24th in the nation in 2006.

research tech transfer
Clare McLean
UW Medicine research contributes to the health of people and the local and global economy.
tech transfer research

The Milken Institute is a non-profit, non-partisan think tank seeking to foster global prosperity through solutions that widen access to capital, create jobs, promote industry expansion and improve health.

Its latest report, “Concept to Commercialization:  The Best Universities for Technology Transfer”  attributed the UW’s rise, in part, to the restructuring of CoMotion, a collaborative innovation hub that expands the economic and social impact of UW discoveries.

The report also highlights the success  of the UW School of Medicine faculty in bringing in more than half of the $1 billion federal research grants awarded to the UW in  2016.

It also mentioned that 27 percent of the start-ups  in the CoMotion labs were in the biotech and health-care fields.

While not listed specifically in the Milken report, a few examples of start up companies launched in 2015 from UW medical advances are:

Aoartic Corporation:  This company is developing patient-specific treatments for abdominal aortic aneurysms precisely matched to their anatomy.  It is based on advances by UW Medicine vascular and endovascular surgeons and their collaborators.

C-SATS:  A performance management system, created by UW Medicine urologists, UW engineers and others, evaluates and helps improve technical skills in the health professions.

Cyrus Biotechnology:  Easy-to-use software packages are produced by UW Medicine biochemists, UW computer scientists and others to engineer  new drugs  based on protein molecule design.  

EpiThany is a clinical-stage biotech company working on therapeutic vaccines against solid tumors.  It stems from findings by UW cancer researchers.

Novuson Surgical:  This company is looking at the potential of ultrasound energy to control excessive bleeding from traumatic injuries and during clinical procedures.  It is based  bioengineering, physics and medical advances in applying high intensity focused ultrasound.  

Comments?

Send us your ideas and suggestions.